Frozen-thawed Embryo Transfer in a Natural Cycle: hCG Triggering Versus LH Home Test

A Protocol for a Randomized, Two-Parallel-group Study to Compare the Efficacy of Testing LH Surge at Home Versus Medically Triggered Ovulation With hCG (Pregnyl®) in the Naturally Stimulated Cycle in the Frozen-thawed Embryo Transfer

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03115320

Enrollment

Registered

2017-04-14

Start date

2017-01-31

Completion date

2019-12-31

Last updated

2024-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

The primary aim of this study is to find out if ovulation triggered with hCG provides any additional benefit in comparison to spontaneous LH surge measured with the LH surge home test when transferring frozen-thawed embryo in a natural cycle.

Detailed description

The aim of this study is to find out the best method for the ovulation triggering. We study the live birth rates in the both groups.

Interventions

DRUGHuman chorionic gonadotropin

Human chorionic gonadotropin (Pregnyl, 5000IU) is used in the medication group to confirme the ovulation.

OTHERHome ovulation test

The ovulation in the natural menstrual cycle is confirmed by the home ovulation tests from the urine.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 42 Years

Healthy volunteers

Inclusion criteria

* \- Patient with IVF or ICSI cycle and therefore having frozen-thawed embryos * Regular menstruation cycle * Patient's willingness to participate in the study

Exclusion criteria

* \- Irregular menstrual cycle demanding preparing endometrium with hormones for frozen-thawed embryo * No frozen embryos after IVF cycle * Allergy to Pregnyl® or some of its ingredients in the medication or other contraindications due to Pregnyl®

Design outcomes

Primary

Measure	Time frame	Description
Live birth rate	At possible delivery (about 40 weeks)	Live birth rate

Secondary

Measure	Time frame	Description
Ongoing pregnancy rate	After two weeks	Ongoing pregnancy rate

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026